[Novel pharmacologic form of ondansetron (Zofran)--lingual tablets in the prevention of cytostatic chemotherapy-induced loss of appetite, nausea and vomiting].
Ondanserton (zofran), 16-32 mg/24 hr, lingual tablets, 2 days, was administered in 40 patients with advanced tumors who received combination chemotherapy (ABVD) (9 patients with Hodgkin's disease), CHOP (16--non-Hodgkin's lymphoma), gemzar + cisplatin (6--ovarian and 5--breast cancer), CAF, AC and taxol + carboplatin) (4). Distinct prophylactic antiemetic effect, delayed effect (94%) included, was reported in the CHOP group: full control--64% and partial control in gemzar + cisplatin treatment (27%). Loss of appetite was prevented in most patients receiving CHOP and gemzar + cisplatin. Untoward side-effects of ondansetron were not registered.
N.N. Petrov Research Institute of Oncology, Ministry of Health of the RF, St. Petersburg.
M L
ML
Gershanovich
I A
IA
Beresneva
E V
EV
Makhnova
D000286:Administration, Sublingual; D000328:Adult; D000368:Aged; D000932:Antiemetics / Q000008:administration & dosage / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D001066:Appetite / Q000187:drug effects*; D001761:Bleomycin / Q000009:adverse effects; D003520:Cyclophosphamide / Q000009:adverse effects; D003606:Dacarbazine / Q000009:adverse effects; D004317:Doxorubicin / Q000009:adverse effects; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced / Q000517:prevention & control*; D017294:Ondansetron / Q000008:administration & dosage / Q000627:therapeutic use*; D011241:Prednisone / Q000009:adverse effects; D013607:Tablets; D016896:Treatment Outcome; D014747:Vinblastine / Q000009:adverse effects; D014750:Vincristine / Q000009:adverse effects; D014839:Vomiting / Q000139:chemically induced / Q000517:prevention & control*
D000932:Antiemetics; D013607:Tablets; D001761:Bleomycin; D017294:Ondansetron; D014750:Vincristine; D014747:Vinblastine; D003606:Dacarbazine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone